10-Q: MariMed Inc. Q1 2026 Earnings: Revenue Up, Net Loss Narrows

MariMed Inc. reported a 4.2% increase in revenue for Q1 2026, reaching $39.5 million, while net loss attributable to common stockholders narrowed to $3.8 million.

Summary

• MariMed Inc. reported total revenue of $39.5 million for the first quarter ended March 31, 2026, a 4.2% increase compared to $37.9 million in the same period of 2025.
• Product sales, comprising retail and wholesale, increased by 4.4% and 4.8% respectively.
• Other revenue decreased by 39.2% to $0.2 million, primarily due to the cessation of management and rental income from FSC post-acquisition.
• Gross profit was $15.3 million, a slight increase of 1.2% from $15.1 million in Q1 2025, with gross margin at 38.7% compared to 39.8%.
• Total operating expenses decreased by 5.3% to $15.2 million, mainly due to a significant reduction in bad debt expense.
• Income from operations turned positive at $0.1 million, an improvement from a loss of $0.9 million in Q1 2025.
• Net loss attributable to common stockholders was $3.8 million, an improvement from $5.5 million in the prior year's quarter.
• Adjusted EBITDA, a non-GAAP measure, increased by 43.3% to $3.6 million from $2.5 million in Q1 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with revenue growth and improved operational profitability (Adjusted EBITDA) being key highlights. However, the slight decrease in gross margin and ongoing tax disputes temper the overall sentiment.

Positives

• Revenue increased by 4.2% to $39.5 million, driven by growth in both retail and wholesale product sales.
• Income from operations improved significantly, turning positive at $0.1 million compared to a loss of $0.9 million in the prior year.
• Net loss attributable to common stockholders narrowed to $3.8 million from $5.5 million in Q1 2025.
• Adjusted EBITDA showed strong growth, increasing by 43.3% to $3.6 million, indicating improved operational profitability.
• Bad debt expense decreased substantially by 94.5% to $0.1 million, a positive sign for credit risk management.
• Personnel expenses remained stable as a percentage of revenue, indicating cost control in labor.
• The company is no longer subject to IRC Section 280E due to a recent DOJ order, which will allow for full deduction of ordinary and necessary business expenses in future periods.

Negatives

• Gross margin slightly decreased to 38.7% from 39.8% due to higher employee and facility-related expenses.
• Other revenue saw a significant decrease of 39.2%, primarily due to the FSC acquisition.
• The company is disputing significant tax liabilities with the IRS, with liens filed against the company and FSC, which could materially impact financial position if the outcomes are unfavorable.
• The company has substantial debt obligations, with mortgages and notes payable totaling $79.3 million at March 31, 2026.

Risks

• The cannabis industry is highly regulated, and many aspects of the Company's business involve substantial risk of liability.
• The Company is disputing significant tax liabilities with the IRS, with liens filed against the company and FSC, and an unfavorable outcome could materially impact the Company's operations and financial position.
• The Company's operations are conducted in jurisdictions where cannabis remains illegal under United States Federal laws.
• The Company's future cash needs depend on its ability to raise additional cash through financing activities.
• The Company is subject to ongoing business risks arising in the ordinary course of business that affect the estimation process of the carrying value of assets, the recording of liabilities, and the possibility of various loss contingencies.

Future Outlook

The company continues to focus on executing its strategic growth plan, which includes increasing product brand revenue by strengthening cultivation and processing capabilities, developing and launching innovative new products, broadening distribution networks, and expanding into new markets. Retail store revenue is targeted for increase by driving higher average transactions through an enhanced customer experience and expanding the dispensary footprint. Management believes current cash and future funding opportunities will be sufficient to meet anticipated cash needs for working capital and capital expenditures for at least the next twelve months.

Management Comments

• The company is dedicated to improving lives every day through its high-quality products, its actions, and its values.
• Management believes that Adjusted EBITDA, when reviewed in conjunction with Net income (loss), is a useful measure to assess the Company's performance and liquidity, as it provides meaningful operating results by excluding the effects of expenses that are not reflective of the Company's operating business performance.
• Management believes that investors and analysts benefit from considering Adjusted EBITDA in assessing our financial results and our ongoing business, as it allows for meaningful comparisons and analysis of trends in the business.

Industry Context

StockSavvy.ai notes that MariMed Inc.'s Q1 2026 results reflect the ongoing evolution of the cannabis industry, particularly the impact of regulatory changes and the shift towards more normalized business operations post-pandemic. The increase in revenue and improved operational income, alongside the potential benefits from the recent DOJ reclassification of cannabis, positions the company to potentially benefit from a more favorable tax and regulatory environment.

Comparison to Industry Standards

• While specific comparable companies are not detailed in the filing, MariMed operates as a multi-state cannabis operator. Industry benchmarks for gross margins in the cannabis sector can vary significantly by state and operational model, but the reported 38.7% is within a typical range for the industry, though slightly lower than the previous year's 39.8%.
• The increase in Adjusted EBITDA to $3.6 million indicates a positive trend in operational efficiency, which is a key focus for cannabis companies seeking to achieve sustainable profitability amidst high regulatory burdens and competition.
• The company's net loss narrowing is a positive sign, aligning with a broader industry trend of some operators moving towards profitability as markets mature and operational efficiencies are realized.

Management Changes

Legal Proceedings

• The Company is disputing IRS liens filed against FSC and itself related to tax liabilities for 2023 and 2024, and 2023 respectively. While IRS enforcement is stayed during the dispute, an unfavorable outcome could materially impact the Company's operations and financial position.
• The Company faces claims and threatened claims from former employees alleging wrongful termination and other similar alleged wrongdoing, which the Company disputes and are not material.
• In 2020, a subsidiary's receivable from GenCanna Global Inc. was subject to a Chapter 11 bankruptcy; a settlement reduced the claim, and incremental liquidation distributions were received in 2024 and 2025.

Related Party Transactions

• Lease of corporate offices from an entity with an investment interest by the CEO.
• Procurement of nutrients, lab equipment, cultivation supplies, furniture, and tools from an entity owned by the COO's family.
• Royalty payments on the Bettys Eddies product line to an entity owned by the COO and Chief Commercial Officer.
• Distributions paid to the CEO and COO from a majority-owned subsidiary where they hold minority equity interests.
• Outstanding accounts payable to a third-party company in which the CEO has a controlling interest.
• Cash advances from the CEO for certain operating activities.
• Personal guarantees by the CEO on mortgages with Bank of New England and DSB.

Stakeholder Impact

• Shareholders: The narrowing net loss and revenue growth are positive indicators, but ongoing tax disputes and debt levels present risks.
• Employees: Employment agreements for key executives (CFO and CCO) have been formalized with specific salary and severance terms.
• Creditors: The company has significant debt obligations, and its ability to service this debt will be crucial.
• Suppliers: The company has experienced increased costs for ingredients, nutrients, and packaging due to inflation, but is negotiating with suppliers.

Next Steps

• Continue executing strategic growth plan focused on increasing product brand and retail store revenue.
• Strengthen cultivation and processing capabilities.
• Develop and launch innovative new products.
• Broaden distribution network in existing markets and expand into new markets.
• Drive additional and higher average transactions in existing stores.
• Expand dispensary footprint in current and new markets.
• Monitor guidance from DOJ and IRS regarding the impact of cannabis reclassification on future financial statements.
• Pursue resolution for disputed tax liabilities with the IRS.

Key Dates

Recommendation

MariMed Inc. shows signs of operational improvement with increased revenue and a reduced net loss, alongside a strong increase in Adjusted EBITDA. However, the slight decline in gross margin, substantial debt, and significant ongoing tax disputes with the IRS introduce considerable risk. The recent DOJ reclassification of cannabis is a positive long-term development, but its immediate financial impact is yet to be realized. Given these mixed factors, a 'hold' recommendation is appropriate, suggesting investors monitor the resolution of tax issues and continued revenue growth before considering a more aggressive stance.

Keywords

MariMed Inc., 10-Q, Quarterly Report, Cannabis Industry, Revenue Growth, Net Loss, Adjusted EBITDA, Financial Results, SEC Filing, Ryan Crandall, Employment Agreement